1. Home
  2. CANF vs FTEL Comparison

CANF vs FTEL Comparison

Compare CANF & FTEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$4.23

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Logo Fitell Corporation

FTEL

Fitell Corporation

HOLD

Current Price

$3.27

Market Cap

3.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANF
FTEL
Founded
1994
2007
Country
Israel
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
3.7M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
CANF
FTEL
Price
$4.23
$3.27
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$9,750.00
N/A
AVG Volume (30 Days)
555.6K
331.2K
Earning Date
02-03-2026
11-17-2025
Dividend Yield
N/A
52.98%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$560,000.00
$5,200,138.00
Revenue This Year
$461.72
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.42
52 Week Low
$3.36
$2.91
52 Week High
$46.60
$1,427.20

Technical Indicators

Market Signals
Indicator
CANF
FTEL
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
CANF
FTEL

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

About FTEL Fitell Corporation

Fitell Corp conducts its primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiary, serving personal training studios and commercial gyms. Its product coverage includes four proprietary brands: Muscle Motion for strength-training equipment, Rapid Motion with a focus on commercial items, FleetX for cardio equipment, and Harison for cardio, strength, recovery, and conditioning products. The Company operates in one segment, trading gym equipment, and also provides licensing services and gym equipment to overseas gym studios. Majority of its business is conducted in Australia via its e-commerce platform and third-party sites, with maximum revenue earned from retail.

Share on Social Networks: